Average Insider

Where insiders trade, we follow

$COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Andrew R. Robbins
CEO
205
Employees
$33.49
Current Price
$5.66B
Market Cap
52W Low$3.72
Current$33.4974.4% above low, 25.6% below high
52W High$43.73

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00--All Sells
Sells11$127,400,000.003,500,000
3 monthsBuys00--All Sells
Sells55$139,578,705.403,814,642
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jan 22, 2026
Fairmount Funds Management LLC
Director
Sale3,500,000$36.40$127,400,000.00View Details
Dec 26, 2025
Kearns Evan
Chief Legal Officer
Sale65,000$38.70$2,515,500.00View Details
Dec 26, 2025
Green John L.
Chief Financial Officer
Sale77,000$38.68$2,978,360.00View Details
Dec 26, 2025
Sachs Jessica
Chief Medical Officer
Sale82,642$38.70$3,198,245.40View Details
Dec 26, 2025
Robinson John Edward
Chief Scientific Officer
Sale90,000$38.74$3,486,600.00View Details
1 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
May 4, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Past Earnings

Historical earnings results
Feb 24, 2026
EPS
Estimated-$0.51
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.3.23